Document is current
Any future updates will be listed below
-
Authors
Hoffman, Andrew R.
Raveendran, Subhara
Manjelievskaia, Janna
Komirenko, Allison S.
Winer, Isabelle
Cheng, Jennifer
Bonafede, Machaon
Winer-Jones, Jessamine P.
Miner, Paul
Smith, Alden R. https://orcid.org/0000-0003-1582-534X
-
Funding
Funding for this research was provided by:
Ascendis Pharma
- License Information
-
More Information
Article History
Received: 6 February 2025
Accepted: 21 March 2025
First Online: 22 April 2025
Declarations
:
: Dr. Andrew R. Hoffman has received compensation for consulting services provided to Ascendis Pharma, Inc. This work was not done as part of Dr. Andrew R. Hoffman’s Stanford duties and responsibilities. Janna Manjelievskaia, Isabelle Winer, Jennifer Cheng, Machaon Bonafede, and Jessamine P. Winer-Jones are employees of Veradigm, which received funding from Ascendis Pharma to conduct this study. Subhara Raveendran, Allison S. Komirenko, Paul Miner, and Alden R. Smith are employees of Ascendis Pharma.
: The linked dataset used in this study contained only de-identified data as per the de-identification standard defined in Section §164.514(a) of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) Privacy Rule. The process by which the data were de-identified is attested to through a formal determination by a qualified expert as defined in Section §164.514(b) (1) of the HIPAA Privacy Rule. Because this study used only de-identified patient records, it was no longer subject to the HIPAA Privacy Rule and was therefore exempt from institutional review board approval and obtaining informed consent according to US law. This study was conducted in compliance with the Declaration of Helsinki and only used de-identified data.
